New Report: Men Prefer Medical Cannabis Strains High in THC

Over 35,000 Men Surveyed, Majority Use Cannabis to Treat Mental Health Conditions

NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- RYAH Medtech, Inc. (“RYAH” or the “Company”), a big data and technology company focused on valuable predictive analysis in the global medical plant intake industry, has released a data analytics report on men and their use of medical cannabis. Surveying feedback from 35,069 men over a 22-month period, the report found that men make up approximately 55% of the medical cannabis patient population and men typically have higher levels of previous cannabis experience than females. Remarkably, the top ten health concerns reported by the men surveyed identically mirrored the conditions treated by women in the RYAH patient data pool, with the exception of ADHD.

"Understanding each gender’s relationship with medical cannabis is critical for refining treatments and increasing successful patient outcomes. We were surprised to see that over 77.8% of the males surveyed were using medical cannabis for treatment on a daily or nearly daily basis and many of them had previously used cannabis for medical or recreational purposes. Since this differs significantly with the average female patient’s exposure, we hope that medical providers and researchers will be inspired to further study medical cannabis treatments that are personalized to achieve effective patient outcomes,” said Gregory Wagner, Chief Executive Officer of RYAH.

The top ten medical concerns that the men reported included: anxiety, stress, depression, pain, insomnia, ADHD, mood swings, headaches, fatigue, and social anxiety—9 out of 10 being related to mental health. For their treatment, men preferred strains that are high in THC or a balance of THC:CBD and preferred consumption via smoking and vaporization. The report also went into some of the specific strains; for ADHD, men found relief with AC/DC (>1% THC, 20% CBD, Indica-dominant), Super Lemon Haze (>22% THC, <1% CBD, Sativa-dominant), Sour Tsunami, and Purple Candy (19% TCH, <1% CBD, Hybrid). For PTSD, men preferred Gorilla Glue, 3 Kings, Banana Kush, and Blueberry Cheesecake.

The full report and related insights are available online at:

About RYAH Medtech, Inc.
RYAH is a big data and technology company focused on valuable predictive analysis in the global medical plant intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant medical data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is also relevant for growers, dispensaries and Licensed Processors (LPs) to monitor and manage plant strain effects on patients. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete medical plant lifecycle, from seed to consumption.

Forward-Looking Statements
Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation and United States rules and regulation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to the Company; execution of additional distribution agreements; and the results users may receive from using RYAH are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company’s information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; a novel business model; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the United States; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; and the risk associated with a business in the cannabis industry. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

Public Relations Contact:
Annie Graf / Brittany Tibaldi
KCSA Strategic Communications /
786-390-2644 / 347-487-6794

Investor Relations Contact:
Elizabeth Barker
KCSA Strategic Communications